John F de Groot

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Improving the prognosis for patients with glioblastoma: the rationale for targeting Src
    John de Groot
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 431, Houston, TX 77030 4009, USA
    J Neurooncol 95:151-63. 2009
  2. ncbi Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study
    John F de Groot
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:2689-95. 2011
  3. ncbi High-dose antiangiogenic therapy for glioblastoma: less may be more?
    John F de Groot
    Brain Tumor Center and Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 17:6109-11. 2011
  4. ncbi Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas
    John F de Groot
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 14:279-85. 2008
  5. ncbi Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
    John F de Groot
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:4872-81. 2011
  6. ncbi Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    J F de Groot
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 90:89-97. 2008
  7. ncbi Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation
    John F de Groot
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 88:121-33. 2008
  8. ncbi The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo
    John F de Groot
    The Brain Tumor Center, Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:1934-40. 2005
  9. ncbi Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
    Agda K Lucio-Eterovic
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:4589-99. 2009
  10. ncbi Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma
    Dimpy Koul
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Unit 1002, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 5:637-44. 2006

Research Grants

  1. Predictive Markers of Glioblastoma Response to VEGF Trap
    John de Groot; Fiscal Year: 2007

Detail Information

Publications22

  1. ncbi Improving the prognosis for patients with glioblastoma: the rationale for targeting Src
    John de Groot
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 431, Houston, TX 77030 4009, USA
    J Neurooncol 95:151-63. 2009
    ..This review will focus on dasatinib, the most advanced Src inhibitor being tested in glioblastoma, which is currently in phase I/II trials in this setting...
  2. ncbi Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study
    John F de Groot
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:2689-95. 2011
    ..This single-arm phase II study evaluated the efficacy of aflibercept (VEGF Trap), a recombinantly produced fusion protein that scavenges both VEGF and placental growth factor in patients with recurrent malignant glioma...
  3. ncbi High-dose antiangiogenic therapy for glioblastoma: less may be more?
    John F de Groot
    Brain Tumor Center and Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 17:6109-11. 2011
    ..The long-term efficacy of bevacizumab and other antiangiogenic agents is limited, however, because of the rapid development of resistance. Alternative dosing approaches may be one mechanism of prolonging therapeutic efficacy...
  4. ncbi Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas
    John F de Groot
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 14:279-85. 2008
    ..The impact of cytotoxic chemotherapy on the efficacy of bevacizumab and the effect of this therapy on overall survival are important questions that remain to be answered...
  5. ncbi Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
    John F de Groot
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:4872-81. 2011
    ..We investigated potential blood-based markers associated with radiographic changes to aflibercept, which binds VEGF and placental growth factor (PlGF) in patients with recurrent glioblastoma...
  6. ncbi Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    J F de Groot
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 90:89-97. 2008
    ..Carboplatin plus erlotinib is well tolerated but has modest activity in unselected patients. Future trials should be stratified based on optimal molecular or clinical characteristics...
  7. ncbi Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation
    John F de Groot
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 88:121-33. 2008
    ..These results suggest that AMPA receptors are abundantly expressed in high-grade gliomas and gene silencing of the GluR1 AMPA receptor subunit results in abrogation of AMPA-mediated signaling and tumor growth...
  8. ncbi The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo
    John F de Groot
    The Brain Tumor Center, Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:1934-40. 2005
    ..Further studies will improve our knowledge of the role of glutamate in glioma growth and may provide useful prognostic information and alternative therapeutic targets for the treatment of glioma...
  9. ncbi Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
    Agda K Lucio-Eterovic
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:4589-99. 2009
    ....
  10. ncbi Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma
    Dimpy Koul
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Unit 1002, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 5:637-44. 2006
    ..This decrease in cell growth stemmed from the induction of apoptosis. Collectively, these results provide a strong rationale for the pharmacologic targeting of Akt for the treatment of gliomas...
  11. ncbi Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma
    Dimpy Koul
    Brain Tumor Center, Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 100, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Mol Cancer Ther 4:1681-8. 2005
    ..Thus, blocking the ILK/Akt pathway is a potential strategy for molecular targeted therapy for gliomas...
  12. ncbi Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
    John F de Groot
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 12:233-42. 2010
    ..This model mimicked many of the histopathologic findings from the human cases and will augment the discovery of alternative or additive therapies to prevent this type of tumor recurrence in clinical practice...
  13. ncbi VEGF Trap induces antiglioma effect at different stages of disease
    Candelaria Gomez-Manzano
    Department of Neuro Oncology, Unit 1002, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:940-5. 2008
    ..Finally, our results indicate that the clinical success of VEGF Trap may depend on a prolonged treatment in combined therapy aiming to simultaneously inhibit angiogenesis and tumor invasion...
  14. ncbi Moving toward molecular classification of diffuse gliomas in adults
    Brett J Theeler
    Department of Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Neurology 79:1917-26. 2012
    ....
  15. ncbi Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Vinay K Puduvalli
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:216-22. 2008
    ..The results also provide support for similar strategies using combination therapies with newer targeted antiangiogenic agents to generate effective therapies against malignant gliomas...
  16. ncbi New molecular targets in malignant gliomas
    John F de Groot
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Neurol 20:712-8. 2007
    ..The purpose of this review is to provide an update on the identification of novel molecular targets in neurooncology and their translation into clinical practice...
  17. ncbi Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
    Yuji Piao
    Brain Tumor Center, Department of Neuro Oncology, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Neuro Oncol 14:1379-92. 2012
    ..Collectively, our results demonstrate a more prolonged decrease in tumor vascularity with bevacizumab than with sunitinib, associated with a delay in the development of hypoxia and sustained reduction of infiltrated myeloid cells...
  18. ncbi Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma
    Aaron P Brown
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Int J Radiat Oncol Biol Phys 86:277-84. 2013
    ..Efficacy and acute toxicity of proton craniospinal irradiation (p-CSI) were compared with conventional photon CSI (x-CSI) for adults with medulloblastoma...
  19. ncbi Multigene sets for clinical application in glioma
    John F de Groot
    Brain Tumor Center, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Compr Canc Netw 9:449-56; quiz 457. 2011
    ..Identification of relevant biomarkers, especially when coupled with clinical trials of newer targeted therapies, will enable better patient stratification and individualization of treatment for patients with glioma...
  20. ncbi Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: a population-based analysis
    Gary V Walker
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:4538-44. 2012
    ..The purpose of this study was to assess what factors influence radiation therapy (RT) utilization in patients with glioblastoma and to ascertain how patterns of care have changed over time...
  21. ncbi Dapsone induced methemoglobinemia in a patient with glioblastoma
    Julie G Walker
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 94:149-52. 2009
    ..Furthermore, given the toxicities of TMP-SMZ and dapsone, further work is needed to determine the threshold CD4(+) count at which empiric prophylaxis should be initiated...
  22. ncbi Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium
    Ramsis K Benjamin
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:65-74. 2004
    ..In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials...

Research Grants2

  1. Predictive Markers of Glioblastoma Response to VEGF Trap
    John de Groot; Fiscal Year: 2007
    ..These studies are critical for establishing which biomarkers are useful in predicting patient response and monitoring treatment progress, as well as forming a baseline for biomarker studies for future trials with anti-VEGF therapies. ..